Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Among authors: mease p. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Mease PJ, et al. Arthritis Rheum. 2005 Oct;52(10):3279-89. doi: 10.1002/art.21306. Arthritis Rheum. 2005. PMID: 16200601 Free article. Clinical Trial.
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Keeling SO, et al. Among authors: mease pj. J Rheumatol. 2007 Mar;34(3):623-33. J Rheumatol. 2007. PMID: 17343310 Review.
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures.
Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP. Gladman DD, et al. Among authors: mease p. J Rheumatol. 2007 Aug;34(8):1733-9. Epub 2007 Jul 1. J Rheumatol. 2007. PMID: 17611985 Clinical Trial.
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.
Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. Gladman DD, et al. Among authors: mease p. J Rheumatol. 2007 Aug;34(8):1740-5. J Rheumatol. 2007. PMID: 17659754 Clinical Trial.
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E, Heijde Dv, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Keystone E, et al. Among authors: mease p. Arthritis Rheum. 2008 Nov;58(11):3319-29. doi: 10.1002/art.23964. Arthritis Rheum. 2008. PMID: 18975346 Free article. Clinical Trial.
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers.
Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP. Syversen SW, et al. Among authors: mease pj. J Rheumatol. 2009 Aug;36(8):1769-84. doi: 10.3899/jrheum.090262. J Rheumatol. 2009. PMID: 19671812 Review.
682 results